Search Results - Janice Dutcher
- Showing 1 - 7 results of 7
-
1
-
2
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and... by Keith T. Flaherty, Judith Manola, Michael Pins, David F. McDermott, Michael B. Atkins, Janice Dutcher, Daniel J. George, Kim Margolin, Robert S. DiPaola
Published 2015Artigo -
3
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317 by Michael S. Gordon, Michael A. Hussey, Raymond B. Nagle, Primo N. Lara, Philip C. Mack, Janice Dutcher, Wolfram E. Samlowski, Joseph I. Clark, David I. Quinn, Chong‐Xian Pan, David Crawford
Published 2009Artigo -
4
Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer by Ronald M. Bukowski, Fairooz F. Kabbinavar, Robert A. Figlin, Keith T. Flaherty, Sandy Srinivas, Ulka N. Vaishampayan, Harry A. Drabkin, Janice Dutcher, Sarah Ryba, Qi Xia, Frank A. Scappaticci, David F. McDermott
Published 2007Artigo -
5
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 by Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael A.S. Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins, Janice Dutcher, George Wilding, Robert S. DiPaola
Published 2015Artigo -
6
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer by Eric K. Rowinsky, Garry Schwartz, Jared Gollob, John A. Thompson, Nicholas J. Vogelzang, Robert A. Figlin, Ronald M. Bukowski, Naomi B. Haas, Pamela Lockbaum, Yu-Ping Li, Rosalin Arends, Kenneth A. Foon, Gisela Schwab, Janice Dutcher
Published 2004Artigo -
7
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma by Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, Janice Dutcher, Robert A. Figlin, Anil Kapoor, Elżbieta Starosławska, Jeffrey A. Sosman, David McDermott, I. Bodrogi, Zoran Kovačević, Vladimir Lesovoy, Ingo G.H. Schmidt‐Wolf, О. Л. Барбараш, Erhan Gökmen, Timothy E. O’Toole, Stephanie Lustgarten, Laurence Moore, Robert J. Motzer
Published 2007Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Oncology
Adverse effect
Renal cell carcinoma
Cancer
Chemotherapy
Epidermal growth factor receptor
Apoptosis
Bevacizumab
Biochemistry
Cancer research
Chemistry
Confidence interval
Discovery and development of mTOR inhibitors
Erlotinib
Hazard ratio
Hepatocellular carcinoma
Immunology
PI3K/AKT/mTOR pathway
Pharmacology
Sorafenib
Surgery
Temsirolimus
Urology
ABX test
Adjuvant
Alpha interferon
Alternative medicine
Anthropology